E
EdiGene
Genome editing therapeutics and allogeneic CAR-T (MAGIC platform)
About EdiGene
EdiGene is a biotechnology company focused on translating cutting-edge genome editing technologies into novel therapeutics for genetic diseases and cancer. The company leverages proprietary platforms to develop gene editing therapies for a range of diseases and conducts high throughput genome screening to dissect functional big data in biological contexts. EdiGene's proprietary High Throughput Genome Screening Platforms are built on advanced guide RNA design, extensive experience in cell library construction, cellular assays, and deep expertise in computational data analysis. EdiGene operates in the biotechnology and pharmaceutical markets, primarily serving clients in the healthcare sector, including research institutions and pharmaceutical companies. The business model revolves around developing and licensing gene editing therapies and providing high throughput genome screening services. Revenue is generated through partnerships, licensing agreements, and service fees for genome screening. Keywords: genome editing, gene therapy, biotechnology, cancer treatment, genetic diseases, drug discovery, high throughput screening, RNA design, cell library, computational analysis.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Changping District, China
- Employees
- 46
- Open positions
- None listed
- Dealroom signal
- 34.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, DNA, Genetics and genomics, Synthetic Biology, Genome Engineering, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Apr 2021 | $62M | $335M | Alwin Capital · Loyal Valley Capital · IDG Capital · Lilly Asia Ventures | — |
| SERIES BOther financing | Oct 2020 | $67M | $268M | Sequoia · IDG Capital · Lilly Asia Ventures · Huagai Capital | — |
Growth signals
Latest recorded traffic for EdiGene is 2.5K monthly website visits, up 19% over the last three months. EdiGene's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A14 investors entered at this stage
FUJIFILM
IDG Capital
Green Capital Partners
Lilly Asia Ventures
3H Health Investment
Sequoia
Huagai Capital
Green Pine Capital
Kunlun Capital- ACAlwin Capital
Loyal Valley Capital
HongShan
Sherpa Venture Partners
BioTrack Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about EdiGene on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EdiGene’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.